Bone marrow transplantation has been established as a useful treatment for various hematological disorders and is now performed widely, but the mortality rate is still high due to various complications. A clear therapeutic policy for such complications has not yet been established because of their complex nature. We investigated whether the major complications occurring after bone marrow transplantation could be classified as aspects of the systemic inflammatory response syndrome. Subjects were 10 patients who developed severe complications after bone marrow transplantation (graft-versus-host disease, thrombotic microangiopathy, respiratory disorders, and cytomegalovirus interstitial pneumonitis) and 16 patients without complications. Their symptoms, serum cytokines, and factors related to vascular endothelial damage were compared before and after transplantation. Whereas all 10 patients who developed complications had fever in the aplastic phase after transplantation, 15 of the 16 patients without complications remained afebrile (P Ͻ 0.001, t-test). When compared with the patients who did not develop complications, the patients with complications also showed significantly higher cytokine levels during the recovery phase after transplantation (P Ͻ 0.0001, t-test). Thus, the patients with complications developed fever in the aplastic phase and showed an increase of cytokines during the recovery phase, which triggered the occurrence of vascular endothelial damage shown by factors such as the thrombomodulin and plasminogen activator inhibitor type 1. This sequence of events corresponds with that occurring during systemic inflammatory response syndrome, so many of the complications of bone marrow transplantation can be considered as manifestations of this syndrome. Bone Marrow Transplantation (2000) 26, 419-426. 
It is well known that multiple complications can occur after bone marrow transplantation (BMT) as a result of various factors. [1] [2] [3] [4] [5] Control of these complications is complex and difficult, and it is not unusual for there to be an unfavorable outcome. We have previously demonstrated that vascular endothelial damage and hypercytokinemia are involved in central nervous system disorders, 6 adult respiratory distress syndrome (ARDS)-like respiratory disorders, 7 thrombotic microangiopathy (TMA), 8 acute graft-versus-host disease (GVHD), 9 and cytomegalovirus (CMV) infection 10 among the complications occurring after BMT. In this study, we attempted to unify the various complications occurring after BMT by considering them as manifestations of systemic inflammatory response syndrome (SIRS). SIRS is a systemic inflammatory response caused by hypercytokinemia with excess production of proinflammatory cytokines. 11 Organ impairment in SIRS is considered to occur in SIRS secondary to vascular endothelial damage. 12 
Materials and methods

Patients
The subjects were 26 consecutive patients who underwent allogeneic BMT at our institution from October 1996 to June 1998. Table 1 shows age, gender, underlying disease, disease stage, donor type, and human leukocyte antigen (HLA) status of the subjects, as well as conditioning regimen and GVHD prophylaxis. The basic conditioning regimen was busulfan (BU), cyclophosphamide (CY), and total body irradiation (TBI) (BU at a dose of 4 mg/kg/day ϫ 2 days, CY at 30 mg/kg/day ϫ 2 days, and TBI at 3 Gy ϫ 4) or BU and CY (BU at 4 mg/kg/day ϫ 4 days and CY at 60 mg/kg/day ϫ 2 days).
GVHD prophylaxis
The basic treatment was cyclosporin A (CsA) plus methotrexate (MTX) plus methylprednisolone (mPSL) 13 or CsA plus MTX. CsA was infused from day Ϫ1 for 24 h, and was kept at a target blood level of 400-600 ng/ml until marrow engraftment, after which the dosage was varied depending on the symptoms of GVHD. If GVHD became worse, the doses of CsA and mPSL were increased or CsA was replaced with FK506. ALL = acute lymphoblastic leukemia; AML = acute myelogenous leukemia; CML = chronic myelogenous leukemia; MDS = myelodysplastic syndrome; SAA = severe aplastic anemia; ML = mixed leukemia; LBL = lymphoblastic lymphoma; CR1/2 = complete remission 1st/2nd; NR = no remission; CP = chronic phase; AP = accelerated phase; R = related; UR = unrelated; BU = busulphan; CY = cyclophosphamide; TBI = total body irradiation; TLI = total lymphoid irradiation; CsA = cyclosporin A, MTX = methotrexate; mPSL = methylprednisolone.
CMV prophylaxis
We administered acyclovir (250 mg three times daily) from day Ϫ7 to approximately day 30. All patients received 12.5 g of immunoglobulin containing a high titer of anti-CMV antibodies biweekly until 3 months after transplantation. To detect CMV infection, both the bronchoalveolar lavage fluid (BALF) and peripheral blood (PB) were checked for CMV-DNA on approximately day 35 after BMT by the polymerase chain reaction (PCR) method. The direct immunoperoxidase method was also used for CMV antigen screening, employing a peroxidase-labelled monoclonal antibody for matrix protein p65 of CMV (HRP-C7). 14 The HRP-C7 method was used for CMV antigen screening of BALF on day 35 and screening of peripheral blood once weekly until day 50, and then biweekly to monthly depending on the clinical manifestations until day 100. If either the peripheral blood or BALF was CMVpositive by at least one of these methods, ganciclovir was administered according to the schedule proposed by Singhal et al 15 (5 mg/kg twice a day in week 1 and once a day in weeks 2 and 3). Then the dose was adjusted depending on the CMV-DNA level and the C7-HRP antigen in peripheral blood and the extent of myelosuppression in weeks 2 and 3.
Veno-occlusive disease (VOD) prophylaxis
We administered heparin (100 IU/kg/day) for 24 h.
Diagnosis of acute GVHD
The classification of acute GVHD was based on the Seattle diagnostic criteria, and the highest grade until day 100 after transplantation was determined.
Diagnosis of CMV interstitial pneumonitis (CMV-IP)
CMV-IP was diagnosed from the following five criteria: (1) presence of fever, nonproductive cough, tachypnea; (2) hypoxia; (3) radiological findings suggestive of interstitial pneumonitis; (4) detection of CMV-DNA or CMV antigen; and (5) no evidence for another cause of pneumonitis.
Diagnosis of VOD
The diagnosis of VOD was made according to the Seattle clinical criteria, which required at least two of the following three features: hyperbilirubinemia (total serum bilirubin Ͼ2 mg/dl or 34.2 mol/l), hepatomegaly or right upper quadrant pain of hepatic origin, and sudden weight gain (Ͼ2% of baseline body weight) because of fluid accumulation, along with no other explanation for these signs and symptoms.
Diagnosis of thrombotic microangiopathy (TMA)
We made a diagnosis of TMA when the reticulocyte count increased and the platelet count decreased in addition to criteria corresponding to grade 2 or higher of the classification system of Zeigler et al 16 (fragmented erythrocytes comprising at least 1.3% of 2000 counted peripheral blood cells and elevation of LDH).
Assay of cytokines
Levels of the following cytokines were investigated: TNF-␣, IFN-␥, IL-1␤, IL-2, IL-6, IL-8, IL-10 and IL-12. These cytokines were determined on five occasions: (1) before conditioning; (2) day 0 of BMT (before bone marrow infusion); (3) during the aplastic phase after BMT (days 5-10); (4) during the rapid WBC recovery phase (days 11-20); and (5) at the time of WBC stabilization after discontinuation of granulocyte colony-stimulating factor (days 21-28). Blood samples were collected into tubes containing 3.8% citric acid at a ratio of 1:9. After separation by centrifugation at 1500 r.p.m. for 10 min at 4°C, plasma was stored at Ϫ80°C. All parameters were measured in duplicate at each specified time using ELISA kits from TMA = thrombotic microangiopathy; GVHD = graft-versus-host disease; CMV-IP = interstitial pneumonitis due to cytomegalovirus; ARDS = adult respiratory distress syndrome; CRP = C-reactive protein; ANC = absolute neutrophil count; A = alive; D = dead; TTP/HUS = thrombotic thrombocytopenic purpura/hemolytic uremic syndrome; MOF = multiple organ failure.
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Endogen (Woburn, MA, USA) and the mean values were determined.
Assay of plasminogen activator inhibitor type 1 (PAI-1) and thrombomodulin (TM)
17 PAI-1 activity was determined using a commercially available chromogenic assay (Biopool, Ventura, CA, USA) (normal; 4-43 ng/ml). Soluble TM was measured by a commercially available sandwich enzyme immunoassay based on monoclonal antibodies (Fuji-rebio, Tokyo, Japan) (normal р4.5 FU/ml). These parameters were determined three times: (1) during the aplastic phase; (2) during the rapid WBC recovery phase; and (3) at the time of WBC stabilization after discontinuation of granulocyte colonystimulating factor. This study design was prospective, and the data were analyzed blindly and independently. We made the diagnosis of complications without knowledge of the laboratory results and measured the various cytokines and other factors without knowledge of which patients had complications.
Statistical analysis
Statistical analysis was done using Student's t-test or twoway layout analysis of variance as appropriate, and P Ͻ 0.05 was considered to indicate a significant difference. G-CSF (lenograstim (5 g/kg), filgrastim (5 g/kg), or natrograstim (8 g/kg)) was administered to all patients from day 5 until the WBC exceeded 10 ϫ 10 9 /l.
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Results
Among the 26 patients, five developed severe GVHD (grade III or IV), three had CMV-IP, three had TMA, three had ARDS-like respiratory disturbance, and 16 had no complications (Table 2) . Clinical characteristics were compared between the 10 patients with complications and the 16 patients without complications. There were no significant differences in age, sex, underlying disease, conditioning regimen, GVHD prophylaxis, time (days) from BMT to an ANC Ͼ500/l and to a platelet count Ͼ50 000/l, or donor type, but the febrile period during the aplastic phase was significantly longer and the C-reactive protein (CRP) level was significantly higher in patients with complications compared with those without complications (P Ͻ 0.01; t-test).
The changes of various cytokines were studied from before conditioning until the time of WBC stabilization after discontinuation of G-CSF and these parameters were compared between patients with and without each complication. The patients with severe GVHD (grade III or IV) showed a marked rise of IL-10 ( Figure 1a) , those with CMV-IP showed a marked rise of IL-8 ( Figure 1b) and aplastic phase until the time of WBC stabilization and these parameters were compared between patients with and without complications. Both TM and PAI-1 levels were significantly higher at the time of WBC stabilization in the patients with complications compared with the patients without complications (P Ͻ 0.0001; t-test) (Figure 8 ).
Discussion
Various mechanisms have been proposed to explain the complications of BMT, 1-5 but these are diverse and com- plex. By applying the concept of SIRS 11, 12 as the basic state that occurs after BMT, complications such as multiple organ failure can be considered to be derived from SIRS. All of our patients who developed complications had fever during the aplastic phase (Table 2 ) and an increase in cytokines during the recovery phase (different cytokines increased when different complications occurred) ( Figure  1 ). After the increase of cytokines, the serum TM and PAI-1 levels always increased (Figure 8 ). Taking these events into consideration, it seems that the patients were in a similar state to that of SIRS, in which proinflammatory cytokines are overproduced in response to infection (inflammation) and organ impairment or failure is precipitated by these cytokines. Vascular endothelial damage caused by neutrophils has been suggested to be involved in the progression of SIRS to organ impairment, 12 rather than disseminated intravascular coagulation and microthrombus formation as is proposed conventionally. A role for neutrophils would be more consistent with our data. Based on the present findings, patients with fever during the aplastic phase and an increase of pro-inflammatory cytokines (such as TNF-␣, IFN-␥, or IL-12) during the recovery phase who thereafter show an increase in serum TM and PAI-1 (suggesting vascular endothelial damage) seem to be likely to develop complications after BMT. If conditioning with TBI or chemotherapy and the occurrence of fever during the aplastic phase are regarded as the 'first attack' and multiple organ disease syndrome (MODS) arising from vascular endothelial damage primed by cytokines during the recovery phase and triggered by some stimulation (eg CsA or FK506 at high concentrations, or methylprednisolone, GVHD, and CMV infection), is regarded as the 'second attack', then complications such as acute GVHD, VOD, TMA, and CMV-IP after BMT are manifestations of SIRS and the mechanism of onset corresponds to the 'second attack' theory proposed by Ogawa et al. 18 Accordingly, the following preventive measures can be taken to decrease complications after BMT: (1) investigation of new conditioning regimens; (2) prevention of fever during the aplastic phase; (3) adjustment of immunosuppressive therapy after successful graft take; and (4) avoidance of vascular endothelial damage. In this study, we determined the levels of cytokines and indications of vascular endothelial damage throughout the period before and after BMT. Our results suggest that complications after BMT can be regarded as manifestations of SIRS. This concept simplifies the mechanism of complications after BMT, and suggests that countermeasures against infection and vascular endothelial damage are more important than has been realized. (a) TM levels were significantly increased in the recovery phase and stable phase for the patients with than without complications. (b) PAI-1 levels were significantly increased during the recovery phase in the patients with complications compared to those without, and PAI-1 became even higher during the stable phase in the patients with complications.
